

Ministry of Health

Drugs and Devices Division

Drug Submission Status

Report for July 2021

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Accord Healthcare Inc	Ach-Pregabalin	Lyrica	PREGABALIN	225 mg	capsule	02449897
Laboratoire Riva Inc.	Riva-Tadalafil	Cialis	TADALAFIL	5mg	coated tablet	02454726
Laboratoire Riva Inc.	Riva-Tadalafil	Cialis	TADALAFIL	20mg	coated tablet	02454742
Laboratoire Riva Inc.	Riva-Clarithromycin	Biaxin BID	CLARITHROMYCIN	500mg	tablet	02346532
Laboratoire Riva Inc.	Riva-Sildenafil	Viagara	SILDENAFIL	100mg	coated tablet	02452413
Auro Pharma Inc.	Auro-Zolmitriptan	Zomig	ZOLMITRIPTAN	2.5 mg	tablet	02481030

Auro Pharma Inc.	Piperacillin and Tazobactam For Injection	Tazocin	PIPERACILLIN SODIUM & TAZOBACTAM SODIUM	2 g & 250mg	powder for IV injection	02402068
Auro Pharma Inc.	Piperacillin and Tazobactam For Injection	Tazocin	PIPERACILLIN SODIUM & TAZOBACTAM SODIUM	3 g & 375mg	powder for IV injection	02402076
Auro Pharma Inc.	Piperacillin and Tazobactam For Injection	Tazocin	PIPERACILLIN SODIUM & TAZOBACTAM SODIUM	4 g & 500mg	powder for IV injection	02402084
Jamp Pharma Corporation	Jamp Pirfenidone	Esbriet	PIRFENIDONE	267 mg	tablet	02514702
Jamp Pharma Corporation	Jamp Pirfenidone	Esbriet	PIRFENIDONE	801 mg	tablet	02514710